Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial

American Journal of Respiratory and Critical Care Medicine

Volumn 165, Issue 6, 2002, Pages 800-804

  Simonneau, Gerald ^{a,b,c,d,e,f,g,h,i,j,k}   Barst, Robyn J ^{a,b,c,d,e,f,g,h,i,j,k}   Galie, Nazzareno ^{a,b,c,d,e,f,g,h,i,j,k}   Naeije, Robert ^{a,b,c,d,e,f,g,h,i,j,k}   Rich, Stuart ^{a,b,c,d,e,f,g,h,i,j,k}   Bourge, Robert C ^{a,b,c,d,e,f,g,h,i,j,k}   Keogh, Anne ^{a,b,c,d,e,f,g,h,i,j,k}   Oudiz, Ronald ^{a,b,c,d,e,f,g,h,i,j,k}   Frost, Adaani ^{a,b,c,d,e,f,g,h,i,j,k}   Blackburn, Shelmer D ^{a,b,c,d,e,f,g,h,i,j,k}   Crow, James W ^{a,b,c,d,e,f,g,h,i,j,k}   Rubin, Lewis J ^{a,b,c,d,e,f,g,h,i,j,k}  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ERASME HOSPITAL   (Belgium)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g ST VINCENT S HOSPITAL   (Australia)

^h HARBOR UCLA MEDICAL CENTER   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j United Therapeutics Corporation   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Primary pulmonary hypertension; Prostacyclin analogue; Pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts; Pulmonary arterial hypertension associated with connective tissue disease; Treprostinil

Indexed keywords

PLACEBO; PROSTACYCLIN DERIVATIVE; UNCLASSIFIED DRUG; UNIPROST;

ADULT; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INJECTION PAIN; LUNG ARTERIOVENOUS SHUNT; LUNG HEMODYNAMICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

EID: 0037086133     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.165.6.2106079     Document Type: Article

References (26)

1. Primary pulmonary hypertension. A national prospective study
2. Primary pulmonary hypertension
3. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
4. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
5. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
6. Treatment of pulmonary hypertension secondary to connective tissue disease
7. Long term prostacyclin for pulmonary hypertension associated congenital heart defects
8. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
9. Epoprostenol (prostacyclin) and pulmonary hypertension
10. Treatments for severe pulmonary hypertension
11. Orally active prostacyclin analogue in primary pulmonary hypertension
12. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertention
13. Efficacy and safety of UT-15, a prostacyclin analogue for primary pulmonary hypertension
14. Inhaled iloprost to treat severe pulmonary hypertension
15. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
16. The effects of 15AU81, a chemically stable prostacyclin analogue, on the cardiovascular and renin-angiotensin systems of anesthetized dogs
17. The pharmacokinetics and pharmacodynamics of prostacyclin analogue 15AU81 in anesthetized beagle dog
18. Acute hemodynamic effects of 15AU81, a stable prostacyclin analogue, in severe primary pulmonary hypertension
19. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters
20. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
21. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure
22. Psychophysical bases of perceived exertion
23. Patients self-assessment of their congestive heart failure
24. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing
25. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry